(08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients

Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

https://doi.org/10.1101/2020.05.01.20086694

In a retrospective study in patients hospitalized with COVID-19  famotidine use was associated with a significantly reduced risk of clinical deterioration leading to intubation or death. The results were specific for famotidine (no protective association was seen among users of proton pump inhibitors) and also specific for COVID-19 (no protective association was observed for famotidine in patients without COVID-19). A lower peak ferritin value was observed among users of famotidine, supporting the hypothesis that use of famotidine may decrease cytokine release in the setting of SARS-CoV-2 infection.